Introduction During the ongoing COVID‐19 outbreak, face mask use has increased and became a part of our daily lives. While wearing, prolonged contact time and microenvironmental change profoundly lead to an acne flare‐up, defined as “maskne.” Aims We aimed to assess the efficacy and safety of snail secretion filtrate, Calendula officinalis, and Glycyrrhiza glaba root extract combination serum (SCGS) in treating the maskne. Methods This was a randomized, double‐blind, placebo‐controlled trial study. This study enrolled 66 participants with mild‐to‐moderate maskne. The SCGS and placebo were randomly assigned for participants to use twice daily for 12 weeks. Percentage change of acne lesion count, acne severity by Investigator Global Evaluation Acne (IGEA), sebum levels, corneometry levels, transepidermal water loss (TEWL), erythema score by Visia®, and adverse events were evaluated 4‐weekly at baseline to Week 12. At Week 12, all participants evaluated their satisfaction scores using a 10‐point visual analog scale (VAS). Results In the mask‐covered area, the percent reduction in inflammatory acne lesions from the treatment group was significantly greater than the placebo group at all time points (coefficient of percentage change of inflammatory lesions = −33.89 [95% CI −65.24, −2.53]; p = 0.03). Also, a subgroup analysis with participants using concurrent acne treatments revealed similar results (12 participants, coefficient = −50.30 [95% −88.65, −11.95]; p = 0.01). However, there were no significant differences in non‐inflammatory lesions, all skin biophysics, and VAS between groups. Adverse events were mild and occurred in a few cases in both groups. Conclusions The SCGS could significantly improve inflammatory acne lesions and had a favorable tolerability profile, suggesting its role as an adjunctive treatment in maskne.

BackgroundAt present, no predictive models are available to determine the probability of in‐hospital mortality rates (HMRs) in all phenotypes of severe cutaneous adverse reactions (SCARs).ObjectivesOur study explored whether simple clinical and laboratory assessments could help predict the HMRs in any phenotypes of SCAR patients.MethodsFactors influencing HMRs in 195 adults diagnosed with different SCAR phenotypes were identified, and their optimal cut‐offs were determined by Youden's index. Predictive equations for HMRs for all SCAR patients and Stevens‐Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) patients were determined using the exact logistic regression models.ResultsAcute generalized exanthematous pustulosis (AGEP) patients were significantly older, with a short time from drug exposure to reaction, and higher neutrophil count compared to SJS/TEN and drug reaction with eosinophilia and systemic symptoms (DRESS, p < 0.001). Peripheral blood eosinophilia, atypical lymphocytosis and elevated liver transaminase enzymes were significantly higher in DRESS. SJS/TEN phenotype, age ≥ 71.5 years, neutrophil‐to‐lymphocyte ratio ≥ 4.08 (high NLR) and systemic infection were factors predicting in‐hospital mortality in all SCAR subjects. The ALLSCAR model developed from these factors demonstrated high‐diagnostic accuracy for predicting HMRs in all SCAR phenotypes (area under the receiver‐operator curve (AUC) = 0.95). The risk of in‐hospital death was significantly increased in SCAR patients with high NLR after adjusting for systemic infection. The model derived from high NLR, systemic infection and age yielded higher accuracy than SCORTEN (AUC = 0.77) for predicting the HMRs in SJS/TEN patients (AUC = 0.97).ConclusionsBeing older, having systemic infection, having a high NLR and SJS/TEN phenotype increases ALLSCAR scores, which in turn increases the risk of in‐hospital mortality. These basic clinical and laboratory parameters can easily be obtained in any hospital setting. Despite its simple approach, further validation of the model is warranted.